Stephane Boissel is the founder of SparingVision. SparingVision has raised $147M in total funding. Latest round: Series B. Based in Paris, France.
Stéphane Boissel is the President and Chief Executive Officer of SparingVision, a genomic medicine company focused on ocular diseases. The company has raised a total of €119.5 million across two financing rounds. SparingVision aims to develop treatments for inherited retinal diseases (IRDs) and dry age-related macular degeneration (AMD). Prior to joining SparingVision, Boissel held executive roles at Sangamo Therapeutics, TxCell, Genclis, Innate Pharma, and Transgene.
Full founder directory · Investor directory · Company funding database · Fundraising library